首页 | 本学科首页   官方微博 | 高级检索  
检索        

癃清片联合左氧氟沙星治疗IIIA型前列腺炎的疗效观察
引用本文:徐华,商学军,蔡霞,滕文荟,黄宇烽.癃清片联合左氧氟沙星治疗IIIA型前列腺炎的疗效观察[J].中华男科学杂志,2007(4).
作者姓名:徐华  商学军  蔡霞  滕文荟  黄宇烽
作者单位:新疆医科大学第一附属医院生殖助孕中心,南京军区南京总医院男科,新疆医科大学第一附属医院生殖助孕中心,南京军区南京总医院男科,南京军区南京总医院男科 新疆乌鲁木齐830054,南京军区南京总医院男科,江苏南京210002,江苏南京210002,新疆乌鲁木齐830054,江苏南京210002,江苏南京210002
摘    要:目的:探讨癃清片联合左氧氟沙星治疗IIIA型前列腺炎的疗效。方法:选择IIIA型前列腺炎患者80例,随机分为癃清片组(40例)和普乐安片组(40例),均接受相应药物治疗12周。癃清片组先采用癃清片(6片/次,2次/d)联合左氧氟沙星(0.2g/次,2次/d)治疗4周,随后单用癃清片(6片/次,2次/d)治疗8周。普乐安片组先采用普乐安片(4片/次,3次/d)联合左氧氟沙星(0.2g/次,2次/d)治疗4周,随后单用普乐安片(4片/次,3次/d)治疗8周。所有患者治疗前、治疗第4、8、12周末均行NIH-CPSI评分和EPS中WBC计数。结果:癃清片组和普乐安片组患者治疗4、8和12周后,NIH-CPSI总分及其疼痛症状评分、排尿症状评分和生活质量评分均比治疗前有显著降低(P<0.05或0.01),EPS中WBC计数也明显减少(P<0.05)。与治疗第4周末相比,癃清片组治疗第8、12周末的NIH-CPSI总分及其疼痛症状评分、排尿症状评分和生活质量评分的改善情况仍有明显差异(P<0.05),但EPS中WBC计数无明显改变((P>0.05);而治疗第8、12周末的各指标之间差异无显著性(P>0.05)。而普乐安片组治疗第4、8、12周末的NIH-CPSI评分以及EPS中WBC计数之间差异无显著性(P>0.05)。此外,癃清片组治疗第4、8、12周末的NIH-CPSI评分与普乐安片组相比差异均有显著性(P<0.05)。结论:癃清片联合左氧氟沙星治疗IIIA型前列腺炎,能有效改善患者疼痛和排尿症状,提高患者生活质量,对降低患者EPS中WBC数目也有一定作用,具有较好的临床价值。

关 键 词:慢性前列腺炎  中成药  癃清片  左氧氟沙星

Longqingpian Combined with Levofloxacin Highly Effective for Type IIIA Prostatitis
XU Hua,SHANG Xue-jun,CAI Xia,TENG Wen-hui,HUANG Yu-feng.Reproductive Medicine Research Center,the First Affiliated Hospital of Xinjiang Medical University,China.Longqingpian Combined with Levofloxacin Highly Effective for Type IIIA Prostatitis[J].National Journal of Andrology,2007(4).
Authors:XU Hua    SHANG Xue-jun  CAI Xia  TENG Wen-hui  HUANG Yu-fengReproductive Medicine Research Center  the First Affiliated Hospital of Xinjiang Medical University    China
Institution:XU Hua~1,2,SHANG Xue-jun~2,CAI Xia~1,TENG Wen-hui~2,HUANG Yu-feng~21.Reproductive Medicine Research Center,the First Affiliated Hospital of Xinjiang Medical University,830054,China, 2.Department of Andrology,Nanjing General Hospital of Nanjing Command,PLA,Nanjing,Jiangsu 210002,China
Abstract:Objective: To study the therapeutic efficacy of Longqingpian combined with Levofloxacin on Type IIIA prostatitis. Methords: Eighty patients with Type IIIA prostatitis were equally randomized into a Longqingpian group and a Puleanpian group, both treated for 12 weeks. The former were given Longqingpian (once 6 tablets, twice a day) combined with Levofloxacin (once 0.2 g, twice a day) during the first 4 weeks, followed by Longqingpian alone (once 6 tablets, twice a day) for 8 weeks. The latter received Puleanpian (once 4 tablets, 3 times a day) combined with Levofloxacin (once 0.2 g, twice a day) in the initial 4 weeks, followed by Puleanpian alone (once 4 tablets, 3 times a day) for 8 weeks. Before and 4, 8, and 12 weeks after the treatment, all the patients were evaluated by The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and EPS examination. Results: After 4-week, 8-week and 12-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life dropped significantly in both groups compared with pre-treatment (P<0.05 or 0.01), so did the leukocyte count in EPS (P<0.05). Compared with the 4-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life were shown to be significantly different (P<0.05) in the Longqingpian group from the 8-week and 12-week treatment, except the leukocyte count in EPS. However, there was no significant difference between the 8-week and 12-week treatment in any of the indexes (P>0.05). Longqingpian effected significant differences in the above indexes (P<0.05), while Puleanpian did not after the treatment (P>0.05). And the lecithin Amato body analysis revealed no significant changes in EPS after the treatment in either group (P>0.05). Conclusion: Longqingpian combined with Levofloxacin is highly effective for Type IIIA prostatitis, by relieving pain and voiding symptoms, decreasing the leukocyte count in EPS and improving the life quality of the patients.
Keywords:chronic prostatitis  Traditional Chinese Medicine  Longqingpian  Levofloxacin
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号